Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
2001 1
2002 14
2003 14
2004 27
2005 21
2006 25
2007 36
2008 36
2009 36
2010 47
2011 52
2012 75
2013 67
2014 81
2015 102
2016 94
2017 105
2018 126
2019 127
2020 88
Text availability
Article attribute
Article type
Publication date

Search Results

1,037 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, Li S, Kimball AB. Blauvelt A, et al. Among authors: li s. J Am Acad Dermatol. 2017 Mar;76(3):405-417. doi: 10.1016/j.jaad.2016.11.041. Epub 2017 Jan 2. J Am Acad Dermatol. 2017. PMID: 28057360 Free article. Clinical Trial.
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB. Reich K, et al. Among authors: li s. J Am Acad Dermatol. 2017 Mar;76(3):418-431. doi: 10.1016/j.jaad.2016.11.042. Epub 2017 Jan 2. J Am Acad Dermatol. 2017. PMID: 28057361 Free article. Clinical Trial.
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Reich K, Armstrong AW, Langley RG, Flavin S, Randazzo B, Li S, Hsu MC, Branigan P, Blauvelt A. Reich K, et al. Among authors: li s. Lancet. 2019 Sep 7;394(10201):831-839. doi: 10.1016/S0140-6736(19)31773-8. Epub 2019 Aug 8. Lancet. 2019. PMID: 31402114 Clinical Trial.
Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.
Griffiths CEM, Papp KA, Kimball AB, Randazzo B, Song M, Li S, Shen YK, Blauvelt A. Griffiths CEM, et al. Among authors: li s. J Drugs Dermatol. 2018 Aug 1;17(8):826-832. J Drugs Dermatol. 2018. PMID: 30124721 Clinical Trial.
The Zinc-Finger Protein ZCCHC3 Binds RNA and Facilitates Viral RNA Sensing and Activation of the RIG-I-like Receptors.
Lian H, Zang R, Wei J, Ye W, Hu MM, Chen YD, Zhang XN, Guo Y, Lei CQ, Yang Q, Luo WW, Li S, Shu HB. Lian H, et al. Among authors: li s. Immunity. 2018 Sep 18;49(3):438-448.e5. doi: 10.1016/j.immuni.2018.08.014. Epub 2018 Sep 4. Immunity. 2018. PMID: 30193849 Free article.
MicroRNA-30a ameliorates hepatic fibrosis by inhibiting Beclin1-mediated autophagy.
Chen J, Yu Y, Li S, Liu Y, Zhou S, Cao S, Yin J, Li G. Chen J, et al. Among authors: li s. J Cell Mol Med. 2017 Dec;21(12):3679-3692. doi: 10.1111/jcmm.13278. Epub 2017 Aug 1. J Cell Mol Med. 2017. PMID: 28766848 Free PMC article.
Immunogenicity of Guselkumab Is Not Clinically Relevant in Patients with Moderate-to-Severe Plaque Psoriasis.
Zhu Y, Marini JC, Song M, Randazzo B, Shen YK, Li S, Zhou H. Zhu Y, et al. Among authors: li s. J Invest Dermatol. 2019 Aug;139(8):1830-1834.e6. doi: 10.1016/j.jid.2019.02.018. Epub 2019 Mar 6. J Invest Dermatol. 2019. PMID: 30851300 Clinical Trial. No abstract available.
ZCCHC3 is a co-sensor of cGAS for dsDNA recognition in innate immune response.
Lian H, Wei J, Zang R, Ye W, Yang Q, Zhang XN, Chen YD, Fu YZ, Hu MM, Lei CQ, Luo WW, Li S, Shu HB. Lian H, et al. Among authors: li s. Nat Commun. 2018 Aug 22;9(1):3349. doi: 10.1038/s41467-018-05559-w. Nat Commun. 2018. PMID: 30135424 Free PMC article.
Caspase-11-mediated tubular epithelial pyroptosis underlies contrast-induced acute kidney injury.
Zhang Z, Shao X, Jiang N, Mou S, Gu L, Li S, Lin Q, He Y, Zhang M, Zhou W, Ni Z. Zhang Z, et al. Among authors: li s. Cell Death Dis. 2018 Sep 24;9(10):983. doi: 10.1038/s41419-018-1023-x. Cell Death Dis. 2018. PMID: 30250284 Free PMC article.
Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study.
Gordon KB, Armstrong AW, Foley P, Song M, Shen YK, Li S, Muñoz-Elías EJ, Branigan P, Liu X, Reich K. Gordon KB, et al. Among authors: li s. J Invest Dermatol. 2019 Dec;139(12):2437-2446.e1. doi: 10.1016/j.jid.2019.05.016. Epub 2019 Jun 15. J Invest Dermatol. 2019. PMID: 31207232 Clinical Trial.
1,037 results
Jump to page
Feedback